#mTOR-targeted
LightNews LightNews
oncodaily.bsky.social
Can We Combine Radiotherapy with CDK4/6i, HER2, PARP or mTOR Targeted Agents? - Paolo Tarantino

@ptarantinomd.bsky.social

oncodaily.com/voices/paolo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Paolo Tarantino: Can We Combine Radiotherapy with CDK4/6i, HER2, PARP or mTOR Targeted Agents? - OncoDaily
Paolo Tarantino: Can We Combine Radiotherapy with CDK4/6i, HER2, PARP or mTOR Targeted Agents? / Ajeet Kumar Gandhi, Anne Hansen Reek, Antonin Levy, Arsela
oncodaily.com
December 15, 2025 at 6:35 PM
commsbio.nature.com
Col9a1b mutant zebrafish reveal lipid and mTOR pathways as therapeutic targets for intervertebral disc degeneration.
@kaguelab.bsky.social

PDF available: doi.org/10.1038/s42003-026-10702-1
Targeted modulation of phosphate and lipid metabolism reduces ligament mineralization in col9a1b deficient zebrafish - Communications Biology
col9a1b mutant zebrafish reveals lipid and mTOR pathways as therapeutic targets for intervertebral disc degeneration.
doi.org
August 25, 2026 at 2:48 PM
philipleungkh.bsky.social
[Paper Skeet-torial]
Can VOCs be used to non-invasively monitor cancer therapy response?

In our latest pilot study in @natureportfolio.nature.com Scientific Reports, we explored the volatilomic signatures of mTOR inhibitor resistance in colorectal cancer.

🔗 nature.com/articles/s41...

1/n
Volatilomic response to targeted cancer therapy in vitro - Scientific Reports
Scientific Reports - Volatilomic response to targeted cancer therapy in vitro
nature.com
June 3, 2025 at 9:07 PM
katysings.bsky.social
‼️ON A MORE POSITIVE NOTE Conclusion: These findings highlight that CBD: THC combination treatment effectively inhibited ovarian cancer cell growth and invasion via oncogenic PI3K/AKT/mTOR signaling and reactivates PTEN. The combination may represent a promising targeted therapeutic approach…
Frontiers | Selective anti-cancer effects of cannabidiol and Δ9-tetrahydrocannabinol via PI3K/AKT/mTOR inhibition and PTEN restoration in ovarian cancer cells
IntroductionOvarian cancer is a highly lethal gynecological malignancy, often diagnosed at advanced stages. Cannabidiol (CBD) and delta-9-tetrahydrocannabino...
www.frontiersin.org
January 10, 2026 at 5:01 PM
david-solomon.bsky.social
Through longitudinal genomic profiling at GBM disease progression post trial therapy, we identified diverse genomic resistance mechanisms to such multi-agent targeted regimens that included MAPK to PI3K-mTOR pathway shift, acquired mismatch repair deficiency, and acquired MGMT gene amplification
February 8, 2026 at 12:12 AM

Interesting data from Aneta Stachowicz on use of mitochondrial targeted sulfide donors in high fat diet mice. www.sciencedirect.com/science/arti...
Mitochondria-targeted hydrogen sulfide donor reduces fatty liver and obesity in mice fed a high fat diet by inhibiting de novo lipogenesis and inflammation via mTOR/SREBP-1 and NF-κB signaling pathway...
Metabolic diseases that include obesity and metabolic-associated fatty liver disease (MAFLD) are a rapidly growing worldwide public health problem. Th…
www.sciencedirect.com
October 10, 2024 at 11:43 AM
zacharywalker.bsky.social
The latest research from our lab - utilizing ribosome profiling to investigate mechanisms of drug resistance in multiple myeloma: aacrjournals.org/mcr/article-...
Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma
Abstract. Protein homeostasis is critical to the survival of multiple myeloma cells. Although this is targeted with proteasome inhibitors, mRNA translation inhibition has not entered trials. Recent wo...
aacrjournals.org
May 19, 2025 at 8:29 PM
onco404.bsky.social
🎗️ March is Kidney Cancer Awareness Month! 🎗️

Targeted therapies (VEGF/R, mTOR and immune checkpoint inhibitors) are frontline standard-of-care & boosting patient outcomes! 🆙🆙🆙

Personalized cancer care is the future for even greater impact 🚀 #KidneyCancerAwarenessMonth #PrecisionOncology #EndCancer
March 13, 2025 at 8:28 AM
onco404.bsky.social
🎗️ March is Kidney Cancer Awareness Month! 🎗️

Targeted therapies (VEGF/R, mTOR and immune checkpoint inhibitors) are frontline standard-of-care & boosting patient outcomes! 🆙🆙🆙

Personalized cancer care is the future for even greater impact 🚀 #KidneyCancerAwarenessMonth #PrecisionOncology #EndCancer
March 13, 2025 at 8:31 AM
rridrobot.bsky.social
RRIDs were included in this in Advanced Science paper. Thanks for making your methods matter! #methodsmatter #RRID #OpenScience
Combined Photothermal and mTOR‐Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple‐Negative Breast Cancer
Read the full paper: Combined Photothermal and mTOR‐Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple‐Negative Breast Cancer
doi.org
February 21, 2026 at 8:05 AM
prepub-singlecell.bsky.social
Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapy #SingleCell 🧪🧬🖥️
https://www.researchsquare.com/article/rs-7614104/latest
October 7, 2025 at 7:01 AM
norgenbiotek.bsky.social
K-ras mutations play a critical role in colorectal cancer progression. Understanding these mutations helps guide targeted therapies.

Explore the science behind it.

#CancerResearch #Genetics

6/8
Scientific diagram showing the role of K-ras mutation in colorectal cancer, illustrating pathways like RAF-MEK-MAPK and PI3K-AKT-mTOR that influence tumor growth, proliferation, and survival.
February 26, 2025 at 4:12 PM
jamaoncology.com
Head and neck cancer is the seventh most common cancer worldwide.

This Review provides an overview of EGFR-targeted therapies in HNSCC.

ja.ma/46EQOZn
Diagram titled "Cetuximab-Based Combination Regimens and Their Molecular Targets" shows T cell, NK cell, tumor cell interactions, and molecular pathways including EGFR, RAS, RAF, MEK, ERK, PI3K, AKT, mTOR involved in cell proliferation, growth, and survival.
September 27, 2025 at 4:00 PM
rridrobot.bsky.social
The authors included RRIDs in their None paper! We value the author's support of reproducibility. #reproducibility #RRID #reproducibility
The role of Ephexin1 in translation and mTOR-targeted cancer therapy
doi.org
September 8, 2025 at 7:01 AM
sciencex.bsky.social
New findings show that the protein MCL1 not only prevents cancer cell death but also regulates tumor metabolism by influencing the mTOR pathway, offering new directions for targeted therapies. doi.org/hbgq7s
Protein MCL1 links cancer cell survival and energy metabolism
A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides fundamental insights into cancer biology.
medicalxpress.com
December 23, 2025 at 3:37 PM
solveme.bsky.social
Your support funds bold ME/CFS and Long Covid research. This year, our Catalyst Award helped expand a promising rapamycin trial—and early results are encouraging. Join our $321,000 match & keep the momentum going. 💙 #MovingTheScienceForward
giving.solvecfs.org/page/FUNRSFN...
Researchers Dr. C. Gunnar Gottschalk and Dr. Avik Roy are pictured. Quote from Dr. C. Gunnar Gottschalk reads, "This funding from Solve M.E. will help us continue enrollment in our ongoing expanded phase and cover the cost of study drug and safety labs. Our goal is to develop a predictive test to identify which patients are more likely to benefit from rapamycin or other mTOR-targeted therapies.” At the bottom of the page are logos for Solve M.E. & the ME/CFS Catalyst Awards.
December 4, 2025 at 6:29 PM
renesugar.bsky.social
mTOR regulates T cell exhaustion and #PD1 –targeted immunotherapy response during chronic viral infection #MECFS #LongCovid

pmc.ncbi.nlm.nih.gov/articles/PMC...
mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection
T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by self-renewing stem-like T cells that provide differ...
pmc.ncbi.nlm.nih.gov
January 13, 2025 at 4:51 PM
kkmurray.bsky.social
(J Proteom) Development and application of a targeted phosphoproteomics method for analysing the mTOR pathway dynamics in zebrafish PAC2 cell line: Publication date: Available online 2 June 2025

Source: Journal of Proteomics

Author(s): Nikolai Huwa, René Schönenberger, Ksenia Groh #MassSpecRSS
Development and application of a targeted phosphoproteomics method for analysing the mTOR pathway dynamics in zebrafish PAC2 cell line
Publication date: Available online 2 June 2025 Source: Journal of Proteomics Author(s): Nikolai Huwa, René Schönenberger, Ksenia Groh
dlvr.it
June 3, 2025 at 2:58 PM
philipleungkh.bsky.social
2/n
🎯 The challenge:
Targeted cancer therapies like mTOR inhibitors often show variable patient responses.

We urgently need non-invasive, repeatable, and real-time biomarkers to track treatment response.

Could VOCs be the answer?
June 3, 2025 at 9:08 PM
rridrobot.bsky.social
The authors included RRIDs in their Brain Research paper! RRIDs improve reproducibility in scientific research. #methodsmatter #OpenScience #reproducibility
Targeted downregulation of insulin signaling restricts human tau pathogenesis by reinstating the aberrant heterochromatin loss and mTOR/4EBP/S6K pathway in Drosophila
doi.org
May 31, 2025 at 7:00 AM
lizdelagarzag.bsky.social
As 2025 comes to an end, one standout advance in pediatric oncology was the identification of PRKG1 as a key driver in rhabdomyosarcoma, linking tumor differentiation to treatment response and paving the way for more precise, targeted therapies.

www.nature.com/articles/s41...
PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma - Nature Communications
Despite frequent AKT/mTOR pathway activation in patient’s rhabdomyosarcoma (RMS), success of AKT inhibitors in the clinical has been limited. Here, using RMS patient-derived models, the authors demons...
www.nature.com
December 19, 2025 at 5:42 PM
onco404.bsky.social
🎗️ March is Kidney Cancer Awareness Month! 🎗️

Targeted therapies (VEGF/R, mTOR and immune checkpoint inhibitors) are frontline standard-of-care & boosting patient outcomes! 🆙🆙🆙

Personalized cancer care is the future for even greater impact 🚀 #KidneyCancerAwarenessMonth #PrecisionOncology #EndCancer
March 13, 2025 at 8:30 AM
onco404.bsky.social
As you said: 🎗️ March is Kidney Cancer Awareness Month! 🎗️

Targeted therapies (VEGF/R, mTOR and immune checkpoint inhibitors) are frontline standard-of-care & boosting patient outcomes! 🆙🆙

Personalized cancer care is the future for even greater impact 🚀 #KidneyCancerAwarenessMonth #EndCancer
March 13, 2025 at 8:29 AM
molbcu.bsky.social
Katie Vaeth and T32 appointee Kate Matlin co-authored a research article
doi.org/10.1158/1541...
Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma
AbstractProtein homeostasis is critical to the survival of multiple myeloma cells. Although this is targeted with proteasome inhibitors, mRNA translation inhibition has not entered trials. Recent work...
doi.org
November 24, 2025 at 7:17 PM
cp-cellreports.bsky.social
Coordinated expression of retained introns and poison exons in renal cell carcinoma
Coordinated expression of retained introns and poison exons in renal cell carcinoma
Martínez et al. identify a set of ccRCC tumors with high levels of intron retention (IR) and poison exon (PE) inclusion, producing transcripts normally targeted by the NMD pathway. These tumors have altered mTOR signaling, are associated with poor prognosis, and have unique signatures of immune cell infiltration.
dlvr.it
July 28, 2025 at 7:50 PM